Any current/future new fundraising through debt or equity?

The company plans to complete the remaining Rs. 600 crore CAPEX out of the Rs. 2,000 crore plan by FY25 without expecting an increase in debt, assuming market recovery begins in Q1 FY25. If the market recovery is delayed, the company may postpone additional CAPEX beyond the original plan by a few quarters to maintain current debt levels. There is no indication of immediate new equity fundraising. The company is maintaining financial discipline and plans to balance CAPEX with profitability, focusing on operating within existing debt limits. Any new CAPEX items beyond the planned Rs. 2,000 crore

Any current/future capex/capital investment/strategic investment?

Remaining CAPEX of approx. Rs. 600 crore from the Rs. 2,000 crore plan will be deployed in FY25, mainly in Specialty Chemicals, Nutrition & Health segments, including agro chemical plants, food and cosmetic-grade niacinamide, value-added diketene derivatives, and new boiler and power plant at Bharuch. Additional CAPEX plans are under internal review based on emerging opportunities and customer traction; any new CAPEX beyond the original Rs. 2,000 crore plan may be delayed by quarters if market recovery is slow. Recent/completed CAPEX includes commissioning of an agro intermediates plant in Q

Future growth expectations in sales/revenue/volumes?

Agrochemical segment expected to recover starting H1 FY25 with volume uptick by end Q4 FY24; potential 20-25% YoY growth anticipated. Specialty Chemicals showing growth in non-agro segments like Diketene derivatives, microbial, CDMO, and Pharma, with capacity utilization targeted at 70%+ within 18 months. Positive momentum in CDMO business, considered the fastest-growing segment in Specialty Chemicals, with prospects in pharma, agro, and semiconductor chemicals. Capacity expansions underway: new agro intermediates and Diketene plants commissioning in Q4 FY24; Niacinamide facility by Q2 FY25. M

Future growth expectations in earnings/operating earnings/profits/EPS?

Agrochemical segment, which contributes about 30% of the business, has declined but is expected to recover with volume growth anticipated from H1 FY25 onwards, potentially leading to overall company growth. Specialty Chemicals, especially CDMO business, is the fastest-growing segment expected to drive future growth, with new opportunities in pharma, agrochemicals, and semiconductor chemicals. Capacity utilization for new plants is expected to reach 70%+ within 18 months as demand recovers. EBITDA margins are currently under pressure due to lower volumes and pricing, but an uptick in margins is

Current/ Expected Orderbook/ Pending Orders?

The company is seeing inquiries from customers who were previously served by the largest competitor, Vertellus, which exited the business. Actual order bookings from these customers are currently small but expected to increase as market demand recovers. For pyridine and picoline products, volumes are already booked for the next few quarters, indicating a good sign of demand recovery. There is good traction and advanced discussions with 4-5 customers for semiconductor chemicals in their CDMO business. Utilization in new capacities, such as the recently commissioned agro intermediates MPP plants

Jubilant Ingrevia LtdQ3 FY24Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹638P/E: 32.9Market Cap: ₹10.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Agrochemical segment expected to recover starting H1 FY25 with volume uptick by end Q4 FY24; potential 20-25% YoY growth anticipated.
Specialty Chemicals showing growth in non-agro segments like Diketene derivatives, microbial, CDMO, and Pharma, with capacity utilization targeted at 70%+ within 18 months.
Positive momentum in CDMO business, considered the fastest-growing segment in Specialty Chemicals, with prospects in pharma, agro, and semiconductor chemicals.
Capacity expansions underway: new agro intermediates and Diketene plants commissioning in Q4 FY24; Niacinamide facility by Q2 FY25.
Market share expected to increase due to competitor exit (Vertellus), potentially capturing 70-80% of displaced volumes in pyridine derivatives.
Overall company growth driven by successful CAPEX execution (Rs. 2,000 crore plan on track) and strategic partnerships.
Lean initiatives and cost controls aimed at improving profitability alongside volume growth.

Margin guidance

Category 3

Agrochemical segment, which contributes about 30% of the business, has declined but is expected to recover with volume growth anticipated from H1 FY25 onwards, potentially leading to overall company growth.
Specialty Chemicals, especially CDMO business, is the fastest-growing segment expected to drive future growth, with new opportunities in pharma, agrochemicals, and semiconductor chemicals.
Capacity utilization for new plants is expected to reach 70%+ within 18 months as demand recovers.
EBITDA margins are currently under pressure due to lower volumes and pricing, but an uptick in margins is expected with market recovery.
Management expects fiscal FY25 to be a growth year, with possibly 20%-25% growth year-on-year in estimates, depending on market conditions.
The company aims to maintain financial discipline while deploying Rs. 600 crore planned CAPEX for FY25, without significantly increasing debt.
New digital and energy efficiency initiatives are expected to improve yield, efficiency, and cost structures in the coming years.

See what Jubilant Ingrevia Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

The company plans to complete the remaining Rs. 600 crore CAPEX out of the Rs. 2,000 crore plan by FY25 without expecting an increase in debt, assuming market recovery begins in Q1 FY25.
If the market recovery is delayed, the company may postpone additional CAPEX beyond the original plan by a few quarters to maintain current debt levels.
There is no indication of immediate new equity fundraising.
The company is maintaining financial discipline and plans to balance CAPEX with profitability, focusing on operating within existing debt limits.
Any new CAPEX items beyond the planned Rs. 2,000 crore will be considered cautiously and likely deferred if markets do not improve.
Net debt as of December 31, 2023 was Rs. 636 crore with a Net Debt to EBITDA ratio of 1.36x; efforts to reduce debt further through lean initiatives are ongoing.

Order book

The company is seeing inquiries from customers who were previously served by the largest competitor, Vertellus, which exited the business.
Actual order bookings from these customers are currently small but expected to increase as market demand recovers.
For pyridine and picoline products, volumes are already booked for the next few quarters, indicating a good sign of demand recovery.
There is good traction and advanced discussions with 4-5 customers for semiconductor chemicals in their CDMO business.
Utilization in new capacities, such as the recently commissioned agro intermediates MPP plants, is expected to ramp up to 70%-80% within 18 months given anticipated market recovery.
Overall, the expectation is that volume uptick and orders will accelerate from Q1 FY25 onwards as agrochemical markets pick up and inventories dry down globally.

See what Jubilant Ingrevia Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Remaining CAPEX of approx. Rs. 600 crore from the Rs. 2,000 crore plan will be deployed in FY25, mainly in Specialty Chemicals, Nutrition & Health segments, including agro chemical plants, food and cosmetic-grade niacinamide, value-added diketene derivatives, and new boiler and power plant at Bharuch.
Additional CAPEX plans are under internal review based on emerging opportunities and customer traction; any new CAPEX beyond the original Rs. 2,000 crore plan may be delayed by quarters if market recovery is slow.
Recent/completed CAPEX includes commissioning of an agro intermediates plant in Q3 FY24, with two more plants planned for Q4 FY24 (diketene derivative expansion and agro active cum intermediate).
A niacinamide plant (cosmetic and food-grade) is expected to start around June FY25.
The company is exploring strategic partnerships and new product segments such as semiconductor chemicals through its CDMO business.
Capital allocation aims at maintaining financial discipline without significant increase in debt assuming market recovery in Q1 FY25.

Track Jubilant Ingrevia Ltd — get its next earnings analysis in your feed

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisJubilant Ingrevia Ltd

Rev 2Mar 3

See where Jubilant Ingrevia Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Jubilant Ingrevia Ltd rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia Ltd against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Jubilant Ingrevia Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →